Patents by Inventor Robert Eilers

Robert Eilers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9173843
    Abstract: A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed pieces. The resulting microparticles hare are highly stable largely independent of the physiochemical properties of the active substance and can be especially suitable for fast release dosage forms of pharmaceuticals.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 3, 2015
    Assignee: Jesalis Pharma GMBH
    Inventors: Detlef Grawe, Sabine Gliesing, Robert Eilers
  • Patent number: 9095783
    Abstract: An arrangement and a method for producing high-purity crystals, such as temperature-sensitive pharmaceutical agents, in a countercurrent crystallization process. The arrangement comprises a plurality of crystallizers, mother liquor lines, each of which has a shut-off valve, and crystallization product lines, each of which has a shut-off valve, so that a mother liquor flow can be generated which is directed from a crystallizer to the second-next crystallizer in the direction of decreasing purity, and a crystallization product flow can be generated which is directed from a to dissolved crystallization product that is about to crystallize to the next crystallizer in the direction of higher purity.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: August 4, 2015
    Assignee: HAPILA GmbH
    Inventors: Detlef Grawe, Robert Eilers, Sabine Gliesing
  • Patent number: 8324412
    Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: December 4, 2012
    Assignee: Bayer Pharma AG
    Inventors: Detlef Grawe, Sabine Gliesing, Hagen Gerecke, Peter Hoesel, Uwe Mueller, Thomas Michel, Robert Eilers, Uwe Knabe, Bernd Erhart, Michael Mosebach, David Voigtlaender, Ulf Tilstam, Jürgen Jacke, Klaus Bahl, Ulf Bohlmann, Dieter Wehmeier, Michael Sander
  • Publication number: 20110257142
    Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).
    Type: Application
    Filed: January 10, 2011
    Publication date: October 20, 2011
    Inventors: Detlef Grawe, Sabine Gliesing, Hagen Gerecke, Peter Hoesel, Uwe Mueller, Thomas Michel, Robert Eilers, Uwe Knabe, Bernd Erhart, Michael Mosebach, David Voigtlaender, Ulf Tilstam, Jürgen Jacke, Klaus Bahl, Ulf Bohlmann, Dieter Wehmeier, Michael Sander
  • Publication number: 20110144071
    Abstract: A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed pieces. The resulting microparticles hare highly stable largely independent of the physiochemical properties of the active substance and can be especially suitable for fast release dosage forms of pharmaceuticals.
    Type: Application
    Filed: June 30, 2009
    Publication date: June 16, 2011
    Applicant: JESALIS PHARMA GMBH
    Inventors: Detlef Grawe, Sabine Gliesing, Robert Eilers
  • Publication number: 20110065952
    Abstract: An arrangement and a method for producing high-purity crystals, such as temperature-sensitive pharmaceutical agents, in a countercurrent crystallization process. The arrangement comprises a plurality of crystallizers, mother liquor lines, each of which has a shut-off valve, and crystallization product lines, each of which has a shut-off valve, so that a mother liquor flow can be generated which is directed from a crystallizer to the second-next crystallizer in the direction of decreasing purity, and a crystallization product flow can be generated which is directed from a to dissolved crystallization product that is about to crystallize to the next crystallizer in the direction of higher purity.
    Type: Application
    Filed: April 29, 2009
    Publication date: March 17, 2011
    Applicant: HAPILA GMBH
    Inventors: Detlef Grawe, Robert Eilers, Sabine Gliesing
  • Publication number: 20090054387
    Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).
    Type: Application
    Filed: April 17, 2007
    Publication date: February 26, 2009
    Inventors: Detlef Grawe, Sabine Gliesing, Hagen Gerecke, Peter Heesel, Uwe Mueller, Thomas Michel, Robert Eilers
  • Publication number: 20060267701
    Abstract: A voltage-controlled crystal oscillator (VCXO) being controllable by a tuning voltage, the VCXO having a crystal and an adjustable capacitor array. In one example, the VCXO includes an analog to digital converter converting the tuning voltage into corresponding digital values; a memory storing one or more parameters of the crystal and tuning profile; and a logic block receiving the digital values and the one or more parameters of the crystal and tuning profile, said logic block dynamically calculating one or more values for use in adjusting the adjustable capacitor array. In this way, the logic block can dynamically calculate and adjust the operations (i.e., the oscillation frequency) of the VCXO in real time.
    Type: Application
    Filed: May 27, 2005
    Publication date: November 30, 2006
    Inventor: Robert Eilers
  • Publication number: 20060212970
    Abstract: The current invention relates to enhancing gene expression in plants. A promoter drives the expression of structural genes or other polynucleotides in the abscission zone of a plant is provided. The sequence of such a promoter, and its use in a transgenic plant comprising such a promoter, is described.
    Type: Application
    Filed: February 13, 2004
    Publication date: September 21, 2006
    Inventors: Deepti Bhat, Robert Eilers, Donald Nelson, Daniel Tennessen